402 related articles for article (PubMed ID: 20364105)
61. Altered regulation of DNA ligase IV activity by aberrant promoter DNA methylation and gene amplification in colorectal cancer.
Kuhmann C; Li C; Kloor M; Salou M; Weigel C; Schmidt CR; Ng LW; Tsui WW; Leung SY; Yuen ST; Becker N; Weichenhan D; Plass C; Schmezer P; Chan TL; Popanda O
Hum Mol Genet; 2014 Apr; 23(8):2043-54. PubMed ID: 24282031
[TBL] [Abstract][Full Text] [Related]
62. Promoter methylation blocks FES protein-tyrosine kinase gene expression in colorectal cancer.
Shaffer JM; Smithgall TE
Genes Chromosomes Cancer; 2009 Mar; 48(3):272-84. PubMed ID: 19051325
[TBL] [Abstract][Full Text] [Related]
63. [Inactivation of PMS2 gene by promoter methylation in nasopharyngeal carcinoma].
Ni HF; Jiang B; Zhou Z; Li Y; Yuan XY; Cao XL; Huang GW
Zhonghua Zhong Liu Za Zhi; 2016 Nov; 38(11):812-817. PubMed ID: 27998438
[No Abstract] [Full Text] [Related]
64. Methylation-Sensitive High Resolution Melting (MS-HRM).
Hussmann D; Hansen LL
Methods Mol Biol; 2018; 1708():551-571. PubMed ID: 29224163
[TBL] [Abstract][Full Text] [Related]
65. Analysis of RET promoter CpG island methylation using methylation-specific PCR (MSP), pyrosequencing, and methylation-sensitive high-resolution melting (MS-HRM): impact on stage II colon cancer patient outcome.
Draht MX; Smits KM; Jooste V; Tournier B; Vervoort M; Ramaekers C; Chapusot C; Weijenberg MP; van Engeland M; Melotte V
Clin Epigenetics; 2016; 8():44. PubMed ID: 27118999
[TBL] [Abstract][Full Text] [Related]
66. Semaphorin-3F functions as a tumor suppressor in colorectal cancer due to regulation by DNA methylation.
Gao X; Tang C; Shi W; Feng S; Qin W; Jiang T; Sun Y
Int J Clin Exp Pathol; 2015; 8(10):12766-74. PubMed ID: 26722466
[TBL] [Abstract][Full Text] [Related]
67. DNA Hypermethylation of SHISA3 in Colorectal Cancer: An Independent Predictor of Poor Prognosis.
Tsai MH; Chen WC; Yu SL; Chen CC; Jao TM; Huang CY; Tzeng ST; Yen SJ; Yang YC
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1481-9. PubMed ID: 25968618
[TBL] [Abstract][Full Text] [Related]
68. Methylation-associated silencing of the Wnt antagonist SFRP1 gene in human ovarian cancers.
Takada T; Yagi Y; Maekita T; Imura M; Nakagawa S; Tsao SW; Miyamoto K; Yoshino O; Yasugi T; Taketani Y; Ushijima T
Cancer Sci; 2004 Sep; 95(9):741-4. PubMed ID: 15471560
[TBL] [Abstract][Full Text] [Related]
69. Retinoic acid-induced 2 (RAI2) is a novel tumor suppressor, and promoter region methylation of RAI2 is a poor prognostic marker in colorectal cancer.
Yan W; Wu K; Herman JG; Xu X; Yang Y; Dai G; Guo M
Clin Epigenetics; 2018; 10():69. PubMed ID: 29796120
[TBL] [Abstract][Full Text] [Related]
70. Aberrant promoter hypermethylation of the CHFR gene in oral squamous cell carcinomas.
Baba S; Hara A; Kato K; Long NK; Hatano Y; Kimura M; Okano Y; Yamada Y; Shibata T
Oncol Rep; 2009 Nov; 22(5):1173-9. PubMed ID: 19787237
[TBL] [Abstract][Full Text] [Related]
71. Van-Gogh-like 2 antagonises the canonical WNT pathway and is methylated in colorectal cancers.
Piazzi G; Selgrad M; Garcia M; Ceccarelli C; Fini L; Bianchi P; Laghi L; D'Angelo L; Paterini P; Malfertheiner P; Chieco P; Boland CR; Bazzoli F; Ricciardiello L
Br J Cancer; 2013 Apr; 108(8):1750-6. PubMed ID: 23579212
[TBL] [Abstract][Full Text] [Related]
72. Aberrant methylation of heparan sulfate glucosamine 3-O-sulfotransferase 2 genes as a biomarker in colorectal cancer.
Tokuyama Y; Takahashi T; Okumura N; Nonaka K; Kawaguchi Y; Yamaguchi K; Osada S; Gazdar A; Yoshida K
Anticancer Res; 2010 Dec; 30(12):4811-8. PubMed ID: 21187457
[TBL] [Abstract][Full Text] [Related]
73. Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer.
Henrique R; Costa VL; Cerveira N; Carvalho AL; Hoque MO; Ribeiro FR; Oliveira J; Teixeira MR; Sidransky D; Jerónimo C
J Mol Med (Berl); 2006 Nov; 84(11):911-8. PubMed ID: 17016690
[TBL] [Abstract][Full Text] [Related]
74. DSS1 promoter hypomethylation and overexpression predict poor prognosis in melanoma and squamous cell carcinoma patients.
Venza M; Visalli M; Catalano T; Beninati C; Teti D; Venza I
Hum Pathol; 2017 Feb; 60():137-146. PubMed ID: 27825810
[TBL] [Abstract][Full Text] [Related]
75. Aberrant hypermethylation of the HOXD10 gene in papillary thyroid cancer with BRAFV600E mutation.
Cao YM; Gu J; Zhang YS; Wei WJ; Qu N; Wen D; Liao T; Shi RL; Zhang L; Ji QH; Wang Y; Sun GH; Zhao YX; Wang YJ; Yu J; Zhu YX
Oncol Rep; 2018 Jan; 39(1):338-348. PubMed ID: 29115628
[TBL] [Abstract][Full Text] [Related]
76. Promoter hypermethylation of DNA damage response genes in hepatocellular carcinoma.
Li Z; Zhang H; Yang J; Hao T; Li S
Cell Biol Int; 2012 May; 36(5):427-32. PubMed ID: 21864295
[TBL] [Abstract][Full Text] [Related]
77. Methylation status of T-lymphoma invasion and metastasis 1 promoter and its overexpression in colorectal cancer.
Jin H; Li T; Ding Y; Deng Y; Zhang W; Yang H; Zhou J; Liu C; Lin J; Ding Y
Hum Pathol; 2011 Apr; 42(4):541-51. PubMed ID: 21237486
[TBL] [Abstract][Full Text] [Related]
78. Involvement of promoter methylation in the regulation of Pregnane X receptor in colon cancer cells.
Habano W; Gamo T; Terashima J; Sugai T; Otsuka K; Wakabayashi G; Ozawa S
BMC Cancer; 2011 Feb; 11():81. PubMed ID: 21342487
[TBL] [Abstract][Full Text] [Related]
79. Interaction of 5-aza-2'-deoxycytidine and depsipeptide on antineoplastic activity and activation of 14-3-3sigma, E-cadherin and tissue inhibitor of metalloproteinase 3 expression in human breast carcinoma cells.
Gagnon J; Shaker S; Primeau M; Hurtubise A; Momparler RL
Anticancer Drugs; 2003 Mar; 14(3):193-202. PubMed ID: 12634613
[TBL] [Abstract][Full Text] [Related]
80. Correlation of deregulated like-acetylglucosaminyl transferase and aberrant α-dystroglycan expression with human tongue cancer metastasis.
Zhang HZ; Xia XY; Zhu F; Shen H; Song K; Shang ZJ
J Oral Maxillofac Surg; 2014 Jun; 72(6):1106-18. PubMed ID: 24629698
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
